Business Wire

Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today

Share

Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005819/en/

The publication marks a clear consensus on allergen immunotherapy (AIT). It was co-authored by 49 world-renowned allergy specialists from 40 countries and coordinated by Professor Giorgio Walter Canonica, Personalised Medicine, Asthma and Allergy, Humanitas University and Research (Milano, Italy) and Professor Cristoforo Incorvaia, Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, (Milano, Italy), with an unrestricted grant from Stallergenes Greer.

The article demonstrates that there is very strong evidence to show that AIT achieves its primary therapeutic goals in patients with respiratory allergies1,2 by reducing the frequency and intensity of symptoms, the use of rescue medications, and improving quality of life for people with allergies.

Personalised medicine is improving the effectiveness and precision of allergy diagnosis and consequently increasing the performance and treatment outcome of AIT.

This landmark publication, which is fully aligned with Stallergenes Greer’s commitment, highlights the unique role of AIT in allergy treatment encompassing the prediction of a successful treatment, the potential prevention or progression of an allergic disease, and the possibility of providing such advances at affordable costs,” states Amer Jaber, EVP Operations Europe and President of Stallergenes SAS, who heads Stallergenes Greer's R&D.

AIT: a medical model of personalised healthcare

The article outlines that personalised allergy care is valuable and may also be preventive by focusing on quality of life, predictive by allowing treatment to be adjusted to the individual’s response and participative by empowering the patient.

AIT is consistent with the three major needs to be met in personalised medicine:
- the identification of the molecular mechanism of the disease,
- the availability of diagnostic tools to recognise this mechanism, and
- the availability of a treatment capable of blocking the mechanism3,4.

AIT delivers customised healthcare, with medical decisions, practices, and/or products tailored to the individual patient5.

Leveraging precision medicine for personalised allergy care

This tailor-made approach to diagnosis, decision-making, product choice and treatment schedules may enhance effectiveness, minimise adverse events, improve quality of life and reduce the socio-economic impact of allergies 6,7,8,9.

Stallergenes Greer’s purpose “Enabling precision medicine to improve life for people with allergies” is in line with the statements set out in the article. Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to maximise treatment outcomes for patients with allergies.

Read the full article here: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14575

ABOUT STALLERGENES GREER Ltd

Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Additional information is available at: https://www.stallergenesgreer.com/


1 Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
2 Demoly P, et al. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):640-648.
3 Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010: 22; 363(4):301-4.
4 Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy. 2015: 8;13:24.
5 Canonica GW, et al. Allergen Immunotherapy (AIT): A prototype of precision medicine. World Allergy Organ J. 2015;8 (1), 31 2015.
6 Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016; 137:545-558.
7 Caillot N, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. J Allergy Clin Immunol. 2017;140; 759-770.
8 Gueguen C, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. Allergy. 2019; 74:2223-2226.
9 Luce S, et al. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy. Allergy. 2020; 75:1513-1516.

Contact information

Communications
Catherine Kress
Tel: +33 01 55 59 26 05
Email: catherine.kress@stallergenesgreer.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Celebrates 15 Years of Delivering Client Success28.9.2020 15:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of business software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that September marks the 15th anniversary of the Company’s founding in 2005 to redefine the enterprise software support market. The Company set out to deliver a premium, ultra-responsive support model, and bring choice and value to software licensees around the world. Since its inception, Rimini Street has continually set the premium standard on what Oracle and SAP licensees should expect from their support experience. The Company is responsible for delivering a long history of innovative “firsts” for the enterprise software support market, including guaranteed ultra-responsive SLA’s, support for customizations at no additional cost, support for at least 15 years without required upgrades or updates and saving clients nearly $5 billion in total maintenance and support cos

Epic Fantasy 3DMMORPG Forsaken World: Gods and Demons Open for Pre-registration Today28.9.2020 15:00:00 CESTPress release

Forsaken World: Gods and Demons is an open-world fantasy MMORPG on an incredible scale. Dive into a world of never-ending adventure where treasure and glory awaits the victor. Raid a dragon's lair, search for lost artifacts, or kick back, relax and catch some fish in between epic adventures. The world around you will be influenced by your in-game decisions, with a storyline that allows you to determine the future of Calindor. Leave your mark and become a legend! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005293/en/ Pre-register now on the App Store and Google Play (Graphic: Business Wire) Endless Character Customization Change your class at any time and specialize your character just the way you want it. Mix and match abilities and talents to fit your combat style, and customize your appearance to bring out the true you, right down to the facial expression. No two players are the same in FW: GD. A Stunning World Im

Hyprevention Raises New Financing to Commercialize Spinal Implant Product V-STRUT© in the USA.28.9.2020 14:55:00 CESTPress release

Hyprevention has raised new financing to support the V-STRUT© Vertebral Implant product. The financing will be used to execute the commercialization plans for the US spinal fracture market. The V-STRUT© Vertebral Implant is indicated for use in the treatment of vertebral fractures. In May 2019, a US patent was granted for V-STRUT© and in March 2020, the device received FDA-510(k) clearance. “We are delighted that our existing investors have shown confidence in our product development efforts and commercialization plans for the US market by increasing their investment in the company,” says Cecile Vienney, CEO. The Hyprevention team has entered into a commercial relationship with DAWA Medical and has received several orders for the product from enthusiastic customers. DAWA Medical, a regional distributor of medical products, will promote sales in Florida, Illinois, Texas and Oklahoma. In addition to DAWA the company is in discussion with other commercial partners to bring the innovative

Mavenir acquires ip.access to expand OpenRAN radio portfolio for CSPs and Enterprise Private Networks28.9.2020 14:00:00 CESTPress release

Mavenir, a leading provider of end-to-end cloud-native Network Software Provider for Communications Service Providers (CSPs) announces today that it has acquired ip.access Ltd, a leading 2G, 3G, 4G and 5G-ready small cell solutions provider. This acquisition extends Mavenir’s leadership in OpenRAN radio on three fronts: Communication Service Providers: Adding 2G and 3G capabilities to the OpenRAN portfolio Enterprise: Adding a full suite of enterprise radio solutions for Mavenir’s Private Network offerings, including OnGo/CBRS certified solutions Nontraditional Networks: Leveraging market leading software defined vRAN solutions for Aviation, Maritime, Rural and Remote networks with next generation solutions in the air, on land and at sea. “Operators are looking to transform their 2G/3G networks as they migrate to 4G and 5G,” said Pardeep Kohli, President and CEO, Mavenir. “We expect to provide a seamless, multi radio access technology single RAN offering for those operators that allows

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics28.9.2020 12:00:00 CESTPress release

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider today announced the launch of pci | bridge, an innovative digital platform that will give customers immediate visibility into their clinical and commercial supply chain, and provide instantaneous data and insights to inform decision-making. Created using an agile development process whereby key clients collaborated and provided input, PCI built an industry-leading digital interface that delivers greater transparency to clients – saving time and resources to ultimately help bring life-changing therapies to patients faster. The launch of pci | bridge is one of many initiatives that PCI has undertaken to incorporate digital transformation as core to its business strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005059/en/ pci | bridge digital platform logo (Photo: Business Wire) “At PCI, we are always loo

MILAN AIRPORTS MALPENSA & LINATE FIRST IN ITALY TO DEPLOY ECAC STANDARD 3 CABIN BAGGAGE SCREENING SYSTEMS WITH SMITHS DETECTION28.9.2020 11:00:00 CESTPress release

Smiths Detection today announced that it has been awarded a contract by SEA Group to support the upgrade of Malpensa and Linate Airports, two of the three international airports in Milan, to the highest security standard for cabin baggage in the industry - ECAC EDS CB C3. As part of the implementation, up to 18 advanced Computed Tomography (CT) screening systems — HI-SCAN 6040 CTiX — will be installed at Milano Malpensa Airport Terminal 1 along with up to 10 more at Milano Linate Airport. Besides providing advanced explosives detection with low false alarm rates, the CT technology allows electronic devices and liquids to remain in bags. SEA Group also selected Smiths Detection’s HI-SCAN 6040 CTiX carry-on baggage scanners to help protect the health of travellers by reducing the number of trays required during security screening and minimising points of contact at security lanes. “As key gateways to the rest of the world for Milan, our priority for Malpensa and Linate airports is to pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom